OCUL — OCULAR THERAPEUTIX, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1393434 ·
Last close
$6.02
Market Cap
$1.32B
52W High
$16.44
52W Low
$5.80
ADV30
2,990,383
Next earnings
2027-02-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 12,874,000 | 11,419,000 | -97,858,000 | -94,782,000 | 605,647,000 | 530,612,000 | 164,698,000 |
| Jun 2026 | 13,475,000 | 11,464,000 | -82,109,000 | -78,763,000 | 671,317,000 | 598,641,000 | 151,276,000 |
| Mar 2026 | 10,785,000 | 9,456,000 | -93,340,000 | -88,612,000 | 732,529,000 | 666,699,000 | 150,955,000 |
| Dec 2025 | 13,250,000 | 11,656,000 | -69,760,000 | -64,654,000 | 808,057,000 | 737,060,000 | 153,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-253,137,000
Investing CF
$-13,898,000
Financing CF
$452,875,000
CapEx
$-13,898,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.46
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,419,180,000
Inventory
$4,260,000
Receivables
$31,388,000
ST Investments
—
EBIT TTM
$-315,596,000
Pretax Income TTM
$-326,811,000
Interest Exp TTM
$11,215,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$50,384,000
EBITDA
$-336,256,000
Free Cash Flow
$-159,983,872
Enterprise Value
$915,742,848
Total Cash
$530,612,000
Total Debt
$80,013,000
Shares Out
220,022,840
Trailing EPS
$-1.44
Book Value
$2.00
ROE
-93.5%
ROA
-42.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,951,000 | -270,017,000 | -265,939,000 | 808,057,000 | 153,747,000 | 654,310,000 | -204,883,000 |
| Dec 2024 | 63,723,000 | -171,781,000 | -193,506,000 | 457,935,000 | 142,591,000 | 315,344,000 | -134,677,000 |
| Dec 2023 | 58,443,000 | -82,382,000 | -80,736,000 | 252,060,000 | 160,929,000 | 91,131,000 | -70,234,000 |
| Dec 2022 | 51,494,000 | -78,654,000 | -71,038,000 | 149,289,000 | 113,910,000 | 35,379,000 | -59,603,000 |
TTM Snapshot
Revenues TTM
$52,054,000
NetIncome TTM
$-301,447,000
OpCashFlow TTM
—
Assets (Latest)
$671,317,000
Forward EPS
$-1.59
Max Pain — expiry 2026-12-18
max pain strike: $8.00 · spot: $5.94 · call oi: 5,549 · put oi: 871
Expected Move to 2026-12-18:
±$0.64
(10.77%) —
implied range
$5.30 –
$6.58
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
| LBRX | LB PHARMACEUTICALS INC | $1.30B | $40.30 | — |
| GPCR | Structure Therapeutics Inc. | $1.30B | $18.17 | — |
| INVA | Innoviva, Inc. | $1.30B | $18.30 | — |
| TYRA | Tyra Biosciences, Inc. | $1.35B | $19.57 | — |
News headlines (Yahoo Finance, 1h cache)
Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
2026-11-12 04:30 · Yahoo
How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success
2026-11-12 03:14 · Yahoo
Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect
2026-11-10 16:21 · Yahoo
Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA on ...
2026-11-10 01:02 · Yahoo
Ocular Therapeutix, Inc. Q3 2026 Earnings Call Summary
2026-11-09 22:10 · Yahoo
Ocular Tx (OCUL) Q3 2026 Earnings Call Transcript
2026-11-09 19:14 · Yahoo
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call
2026-11-09 17:15 · Yahoo
Ocular Therapeutix falls on third quarter earnings miss
2026-11-09 15:39 · Yahoo
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
2026-11-09 12:40 · Yahoo
Ocular Therapeutix: Q3 Earnings Snapshot
2026-11-09 12:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.